CAR-T Cell Therapy Platform
Immuno-Oncology Platform

CAR T-Cell Therapy Platform

CAR T-cell therapy, especially when directed against CD19 for B cell cancers, has demonstrated remarkable efficacy and received FDA approval in 2017. Nonetheless, despite its achievements, there exist challenges that must be addressed for CAR T-cells to realize their complete therapeutic potential against both solid tumors and haematological malignancies. Reaction Biology stands at the forefront of preclinical cancer immunotherapy, providing a wide array of CAR T-cell development services. Our dedicated platform, crafted by our team of immuno-oncology specialists, employs a blend of in vitro and in vivo studies to accelerate your research endeavors.

We offer a range of services, including:

  • Evaluating the potency and pharmacokinetics of your CAR T candidate within in vivo models of cancer biology
  • Assessing the in vitro cytotoxicity of your CAR T candidate across established cancer cell lines
  • Delving into the activation and memory status of CAR T-cells to illuminate their therapeutic potential
  • Testing the efficacy of CAR T candidates in xenograft models of solid tumors

With our platform’s capabilities, we empower you to refine and advance your therapeutic strategies, driving forward progress in cancer immunotherapy.

E-Mail
Contact an expert
Meet us at your next conference
Meet us at your next conference
Share
Share

Strategies for successful
CAR T-cell therapy development

Barriers to effective CAR T-cell therapy encompass on-target off-tumor toxicities, limited anti-tumor activity across diverse tumor profiles, antigen escape, an immunosuppressive tumor microenvironment, and restricted trafficking and infiltration into tumors. Strategies to mitigate these challenges include:

  • Employing assays to evaluate tumor-specific post-translational modifications for refined targeting.
  • Assessing donor-to-donor heterogeneity in response to anti-tumor activity to optimize therapeutic efficacy.
  • Utilizing dual or tandem CARs to target multiple antigens concurrently.
  • Utilizing combination immunotherapy with CAR T-cells and checkpoint blockade, or engineering CAR T-cells to provide immunostimulatory signals.
  • Engineering CAR T-cells to enhance penetration through tumor stroma, or modulating chemokine receptors on CAR T-cells to respond to tumor-derived chemokines.

CAR T-cell therapy platform by Reaction Biology

  • Haematological malignancies
  • Solid tumor
Haematological malignancies

Our robust CD19 CAR T cell assay suite is ideal for you to study the efficacy and pharmacokinetic properties by monitoring the anti-CD19 CAR T-cells in various preclinical in vitro and in vivo assay models.

Case I: Assess donor-to-donor variability of CD19 CAR T-cells in B cell leukemia model

Case II: Measure in vitro cytotoxicity of CD19 CAR T-cells in NALM-6 and MOLM-13 cell lines

Case III: Evaluate the activation and memory status of CD19 CAR T-cells via flow cytometry

Solid tumor

Our scientists have rigorously optimized the development of various in vivo and in vitro service portfolio to evaluate novel CAR T-cells, with a specific focus on addressing the challenges associated with CAR T therapy for solid tumors.

Case IV: Anti-tumor activity of CAR T-cells in NSG mice engrafted with a subcutaneous THP-1 xenograft tumor model